-
TaqI Restriction Endonuclease: Practical Guide
2026-09-11
TaqI Restriction Endonuclease (SKU K3053) provides rapid, sequence-specific cleavage of plasmid DNA, PCR products, and genomic DNA at the TCGA recognition site. It is intended for research workflows such as cloning and DNA analysis, not for diagnostic or medical use.
-
Adefovir Pharmacokinetics and OAT1 Phenotyping
2026-09-11
The 2024 reference study uses population pharmacokinetic modeling to explain why adefovir exposure rose modestly in a transporter cocktail without evidence of altered renal OAT1 elimination. Its analysis separates apparent absorption or prodrug conversion effects from renal disposition and supports renal clearance as a practical OAT1 phenotype metric at the studied doses.
-
ONX-0914 (PR-957) Workflow for Immune Assays
2026-09-10
ONX-0914 (PR-957) provides a selective way to interrogate LMP7-dependent cytokine signaling without intentionally targeting the constitutive β5 proteasome subunit. This workflow connects concentration-response design, PBMC cytokine profiling, autoimmune-model interpretation, and troubleshooting while using a neuroscience study as a guide for stronger causal assay architecture.
-
NAT1–ENO1–Lactate Axis in Colorectal Cancer
2026-09-10
A 2026 MedComm study identifies a metabolic–immune circuit in colorectal cancer in which NAT1 restrains ENO1-driven glycolysis and lactate production, while NAT1 loss promotes TRAF6-dependent stabilization of PD-L1. The findings connect tumor lactate metabolism with immune-checkpoint regulation and provide a mechanistic framework for studying responses to PD-1 or PD-L1 blockade.
-
Acetylcholine Chloride and Gut-Brain Translation
2026-09-09
The gut-brain cholinergic axis is emerging as a mechanistic bridge between microbiota biology and seizure control. This thought-leadership article explains how Acetylcholine Chloride can support causal pharmacology, circuit-level validation, and translational decision-making without being mistaken for a substitute for microbial or vagal mechanisms.
-
JHU-083: Glutaminase Pathway Research Workflows
2026-09-09
JHU-083 is a selective glutaminase research tool for studying cerebral CD11b cells, glutamate regulation, and experimental cerebral malaria. This workflow-focused guide connects its neurological applications with a recent oxidative-stress study while clearly separating established evidence from transferable assay design.
-
ECL Chemiluminescent Substrate Detection
2026-09-08
The ECL Chemiluminescent Substrate Detection Kit (Hypersensitive) uses horseradish peroxidase (HRP) chemiluminescence for sensitive immunoblot detection on nitrocellulose and PVDF membranes. Product information describes low-picogram sensitivity, a 6–8 hour optimized signal window, and working-reagent stability for 24 hours.
-
Renal OCT2 and MATE1 Inhibition by 5-HT3 Antagonists
2026-09-08
George and colleagues systematically compared five 5-HT3 receptor antagonists for inhibition of the renal organic cation transporters OCT2 and MATE1. Their two-model in vitro design identified compound- and transporter-specific potency differences and showed that selected antagonists can reduce vectorial cation transport, providing a mechanistic basis for evaluating renal drug–drug interaction risk.
-
Toremifene for Breast Cancer: 20 Years of Evidence
2026-09-07
This review synthesizes two decades of clinical and pharmacologic evidence positioning toremifene as a selective estrogen receptor modulator for postmenopausal, hormone-sensitive breast cancer. Its main contribution is a balanced comparison with tamoxifen and aromatase inhibitors, emphasizing pharmacokinetic differences, CYP2D6 considerations, efficacy, safety, and individualized endocrine treatment.
-
Neticonazole Hydrochloride Research Guide
2026-09-07
Neticonazole Hydrochloride supports two distinct research workflows: topical antifungal evaluation against cutaneous Candida models and exploratory colorectal cancer research focused on exosome release and apoptosis. This guide connects diagnostic principles, assay design, formulation handling, and troubleshooting without treating preclinical oncology findings as clinical evidence.
-
VER 155008: HSP 70 Inhibitor Workflow
2026-09-05
Build reproducible biochemical, cancer-cell, and host-factor assays around VER 155008, an adenosine-derived HSP 70 inhibitor that connects ATPase inhibition with chaperone-dependent phenotypes. This guide translates HSC70-mediated viral internalization findings into carefully controlled assay choices without overstating antiviral or in vivo efficacy.
-
Trolox for Redox-Controlled Organoid Assays
2026-09-04
Trolox adds a practical redox-control layer to pancreatic ductal organoid workflows, antioxidant assays, and oxidative injury research. This guide shows how to formulate, dose, benchmark, and troubleshoot Trolox without confusing cytoprotection with altered organoid growth or assay artifacts.
-
Brefeldin A Workflows for ER Stress Studies
2026-09-04
Brefeldin A converts a defined ER-to-Golgi trafficking block into a practical system for studying secretion, ER quality control, and cancer-cell phenotypes. This guide connects concentration and time-course design with apoptosis, migration, and UBR1/UBR2-centered ER stress assays.
-
From hly Biology to Better qPCR Translation
2026-09-03
A translational guide to using mechanistic gene-expression data from Listeria monocytogenes biofilm research to design faster, more reproducible, and better-controlled qPCR workflows.
-
Docking Vitamins Against SARS-CoV-2 Targets
2026-09-03
The reference study used virtual screening, molecular docking, and molecular dynamics simulations to evaluate repurposed vitamins against the SARS-CoV-2 spike receptor-binding domain and 3CL protease. Its main contribution is a dual-target computational framework that links predicted inhibition of viral entry with interference in viral polyprotein processing, while also highlighting the need for biochemical and cellular validation.